Executive Summary
A Regulated Life Sciences organization sits on two very different kinds of knowledge at once: broad, slow-changing protocol and regulatory documentation that every scientist and compliance reviewer needs fast access to, and narrow, highly sensitive study-specific data — assay results, patient-adjacent data, IP-sensitive findings — that must never leak beyond a tightly controlled boundary. Most off-the-shelf AI tools force a choice between the two: broad but ungoverned, or governed but too rigid to actually help researchers move faster.
Vertiva's architecture is built around exactly this split. A horizontal knowledge platform handles the broad protocol and regulatory search every biotech needs, while a second, deeply customized layer — schema, AI agents, and analysis tooling trained on the organization's own data — handles the sensitive, high-value research work, gated behind a data-discovery phase before any deeper commitment is made. The result is a platform that gets safer as it gets more useful, not the other way around.
The Business Problem
Research teams lose measurable time simply locating the right protocol, regulatory precedent, or prior study finding, and that time cost compounds across every active program. At the same time, the organization's most valuable knowledge — its own study data — is also its most dangerous to expose: it contains IP the company cannot afford to leak, and often data adjacent to PII/PHI that carries real regulatory exposure if mishandled. Layered on top of both problems is a talent constraint: the data engineers, MLOps specialists, and platform engineers needed to build this kind of system internally are scarce and expensive, and stand-up time is measured in quarters.
The Vertiva Answer: Two Products, One Foundation
Rather than a single undifferentiated build, the platform separates into two coordinated products on one technical foundation:
| Product | What it delivers |
|---|---|
| Enterprise Knowledge Platform | Document search (RAG), workspace tagging, AI governance, and SOC 2 compliance — generic infrastructure resellable to any biotech, not exclusive to one customer. |
| Vertically Customized R&D Layer | A schema pipeline with automated PII/IP stripping & AI agents trained on the organization's own protocols and terminology. |
Automated De-Identification at the Point of Ingestion
Every document entering the customized research layer passes through an automated normalization pipeline that strips PII and IP-sensitive content before it ever reaches a model or downstream system. Compliance is engineered into the pipeline itself rather than bolted on afterward — every downstream use, from search to cross-study analysis, starts from data that is already clean.
Agents That Speak the Organization's Own Language
Rather than generic industry templates, the platform trains AI agents on the organization's own protocols, terminology, and workflows — the difference between an assistant that understands a company's specific research conventions and one that has to be re-taught them in every conversation.
Compliance and Data Sovereignty Where It Matters Most
Because study data can be adjacent to regulated health information, the platform's self-hosted inference option keeps content inside the organization's own boundary rather than sending it to a third-party model provider, and any configuration that would send data off-boundary is disabled by default until a signed BAA and an egress review are complete. SOC 2 Type II evidence-gathering begins at the platform's foundational rollout, not once a customer asks for it — so the certification clock is already running by the time deeper research work begins.
Conclusion
For a regulated life sciences organization, the highest-value AI investment isn't a single generic assistant — it's a platform disciplined enough to keep sensitive study data locked down while still making it genuinely more useful, one governed layer at a time. That is precisely the sequencing this platform is built to deliver.